// App-Quantinova.ai

e16061 : Abiraterone acetate followed by enzalutamide in chemotherapy-nave metastatic castration-resistant prostate cancer (mCRPC) treated in the US Oncology Community Setting.

Researchers

Presenter

  • Nicholas J. Vogelzang

Principal Investigators

  • Lina Asmar

  • Yvette Ng

  • Maneesha Mehra

  • Debra A. Patt

  • Jun Tang

  • Mark Yap

  • Mary Beth Todd

Medical Centers

  • Carolina Urologic Research Center, The US Oncology Network, Myrtle Beach, SC

  • Johnson & Johnson, Raritan, NJThe US Oncology Network, The Woodlands, TXMcKesson Specialty Health, The Woodlands, TX

  • Janssen Global Services, Raritan, NJ

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Enzalutamide

Outcome

  • N/A

Study Design

  • observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved